Oncogenic Mutations Regulate Tumor Microenvironment through Induction of Growth Factors and Angiogenic Mediators

Activating mutations in the tyrosine kinase domain of HER2 (ErbB2) have been identified in human cancers. Compared to wild-type HER2, mutant HER2 shows constitutively activate kinase activity and increased oncogenicity. Cells transformed by mutant HER2 are resistant to EGFR tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shizhen Emily, Yu, Yang, Criswell, Tracy L., DeBusk, Laura M., Lin, P. Charles, Zent, Roy, Johnson, David H., Ren, Xiubao, Arteaga, Carlos L.
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883631/
https://www.ncbi.nlm.nih.gov/pubmed/20383197
http://dx.doi.org/10.1038/onc.2010.112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883631/
https://www.ncbi.nlm.nih.gov/pubmed/20383197
http://dx.doi.org/10.1038/onc.2010.112

Ejemplares similares